Skip to Content

Can Small Be Big Again?

Serial entrepreneur Larry Bock has confidence in nanotech.
August 1, 2005

When serial entrepreneur Larry Bock’s Palo Alto startup, Nanosys, pulled its IPO a year ago this month, it helped to deflate financial interest in nanotech. But Bock, Nanosys’s chairman, says his confidence in nanotech’s future has not diminished.

Skeptics call nanotech a great collection of small markets with no killer app. That’s probably true in the short term, but even three years out, some of the things we’ll see will be monumentally world changing.

Is the federal National Nanotechnology Initiative (NNI) helping things along?
One of the industry’s ongoing problems is the gap between basic and applied research. People call it “the valley of death” – too big or long-range for the VCs to handle, too applied for academics. NNI should be a helpful bridge.

Environmentalists have nanotechnology on their watch list. Are you worried about a repeat of what happened with genetic engineering?
It has people in the industry concerned, sure. The big difference is that unlike genetic engineering, nanotechnology is a thousand different things. There’s an obvious distinction between using metric tons of carbon nanotubes to fill tires versus someone making a single nanowire sensor. That’s why you need to open a dialogue with critics and start doing an individual risk-benefit analysis for every application.

More evidence that the blanket term “nanotech” is pretty useless?
There’d be a lot less hype and confusion if everyone used the NNI definition – exploiting novel properties and functions of materials in the sub-100-nanometer size range. I don’t think golf balls loaded with nanomaterials should necessarily be labeled nanotechnology.

Keep Reading

Most Popular

This startup wants to copy you into an embryo for organ harvesting

With plans to create realistic synthetic embryos, grown in jars, Renewal Bio is on a journey to the horizon of science and ethics.

VR is as good as psychedelics at helping people reach transcendence

On key metrics, a VR experience elicited a response indistinguishable from subjects who took medium doses of LSD or magic mushrooms.

This nanoparticle could be the key to a universal covid vaccine

Ending the covid pandemic might well require a vaccine that protects against any new strains. Researchers may have found a strategy that will work.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.